Akorn Inc.  (AKRX) Trade Now »     Rate AKRX  -  Discuss AKRX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

AKRX: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

in AKRX

73%

-27.27% in 313 days In Search of Healthcare Diamonds in the Rough <> While we are not even halfway through January, the healthcare sector is already active with deal-making, ranging from the rumored $95 buyout of biotech giant Genetech (DNA) by Roche (RHHBY) to Endo's (ENDP) purchase of small-cap, specialty pharma Indevus (IDEV) to Sequenom's (SQNM) $41M offer for emerging diagnostic company EXACT Sciences (EXAS) – which was promptly rebuffed by EXACT's board after the market close on Monday on the promise of a better deal in the works for shareholders. Larger bio-pharma and diagnost... Continue reading »

Analysis of Generic Drug Companies from India AKRX

73%

+53.85% in 49 days (closed on 01/13/09) Analysis of Generic Drug Companies from India <> The accompanying table includes the Top 25 rated companies with market caps over $50M U.S. Dollar which are included in the ETF Innovators [ETFI] Indian Generic Drug Index as a major component in the Global Generic Drug Index. The index also includes three companies based outside of India – Akorn (AKRX), Caraco Pharma (CPD), and Taro Pharma (TAROF). Akorn has a joint venture with Strides Arcolab (Akorn-Strides, LLC) which is focused on the hospital market for generic injectables, dominated by Hospira (HSP) and... Continue reading »

Bullish on AKRX ... AKRX

16%

-78.29% in 695 days "Akorn Inc (NASDAQ:AKRX), which manufactures and markets sterile pharmaceuticals, declared on 5 December that the company has submitted the first Abbreviated New Drug Application (ANDA) with the Office of Generic Drugs on behalf of Serum Institute of India Ltd, a vaccine manufacturer." http://www.tradingmarkets.com/.site/news/Stock%20News/888473/... I believe this stock is promising. Continue reading »

From the Blogosphere

Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report

The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Earnings:Akorn, Inc. (NASDAQ: AKRX) – consensus loss $0.08American Apparel (NYSE: APP) – consensus EPS $0.03Beazer Homes USA Inc. (NYSE: BZH) – consensus loss $1.24CGGVeritas (NYSE: CGV) – consensus EPS $0.15China Yuchai International (NYSE: CYD) – no consensusCPI Aerostructures (NYSE: CVU) – consensus EPS $0.20Dawson Geophysical (NASDAQ: DWSN) – consensus loss $0.15Elixir Gaming Technologies Inc. (NYSE: EGT) – no consensusEpicept Corp. (NASDAQ: EPCT) – consensus lo... Continue reading »

Trading Radar: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report

The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Earnings:Akorn, Inc. (NASDAQ: AKRX) – consensus loss $0.08American Apparel (NYSE: APP) – consensus EPS $0.03Beazer Homes USA Inc. (NYSE: BZH) – consensus loss $1.24CGGVeritas (NYSE: CGV) – consensus EPS $0.15China Yuchai International (NYSE: CYD) – no consensusCPI Aerostructures (NYSE: CVU) – consensus EPS $0.20Dawson Geophysical (NASDAQ: DWSN) – consensus loss $0.15Elixir Gaming Technologies Inc. (NYSE: EGT) – no consensusEpicept Corp. (NASDAQ: EPCT) – consensus lo... Continue reading »

Small cap, high growth healthcare trio

16%

Jim Oberweis, Jr., money manager and editor of The Oberweis Report, is a long-standing expert in small cap, high growth stocks, trading at reasonable valuations relative to their growth rates. Here, the advisors looks at a trio of specialty healthcare companies involved in niche markets such as women's health, autoimmune disease and vaccines. <>"The Female Health Company (NYSE: FHC) manufactures and markets the femalecondom. This product currently is the only medical device approvedby the FDA under a woman’s control intended to prevent unintended pregnancies and the spread of sexually-transmi<><><><><><><><><><><><>< />... Continue reading »

Morning Movers 12/31: Puget Energy (PSD) Up After Buyout Gets Okay; VeriFone (PAY) Lower On 10-K Delay

StreetInsider.com Morning Movers: <>Akorn, Inc. (NASDAQ: AKRX) 44% HIGHER; Akorn-Strides, LLC announced that the FDA has granted approvals for two Abbreviated New Drug Applications for Sterile Vancomycin HCl USP, 500 mg/vial, 1 g/vial and Sterile Vancomycin HCl USP, 5 g/vial Pharmacy Bulk Package. Akorn-Strides, LLC is a Joint Venture that was formed in 2004 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited. Labopharm Inc. (Nasdaq: DDSS) 43% HIGHER; announced that RYZOLT, its once-daily formulation of the analgesic tramadol, has been approved by the FDA. RYZOLT is indicated for the man... Continue reading »

Analysis of Generic Drug Companies from India

73%

The accompanying table includes the Top 25 rated companies with market caps over $50M U.S. Dollar which are included in the ETF Innovators [ETFI] Indian Generic Drug Index as a major component in the Global Generic Drug Index. The index also includes three companies based outside of India – Akorn (AKRX), Caraco Pharma (CPD), and Taro Pharma (TAROF). Akorn has a joint venture with Strides Arcolab (Akorn-Strides, LLC) which is focused on the hospital market for generic injectables, dominated by Hospira (HSP) and APP Pharma, which was acquired by Fresenius Medical (FMS). Taro is involved ... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.